Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “market outperform” rating reissued by equities researchers at JMP Securities in a report issued on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. JMP Securities’ price target suggests a potential upside of 126.24% from the company’s current price.

TSHA has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday. Canaccord Genuity Group decreased their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $6.38.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $2.21 on Tuesday. The business’s fifty day moving average price is $1.97 and its 200 day moving average price is $2.39. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The stock has a market capitalization of $452.92 million, a PE ratio of -11.15 and a beta of 0.44. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same period last year, the business posted ($0.38) earnings per share. Equities research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently added to or reduced their stakes in the stock. Creative Planning acquired a new position in shares of Taysha Gene Therapies in the third quarter valued at $28,000. Principal Financial Group Inc. acquired a new position in shares of Taysha Gene Therapies in the second quarter valued at $48,000. China Universal Asset Management Co. Ltd. raised its stake in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after acquiring an additional 17,446 shares in the last quarter. Intech Investment Management LLC acquired a new position in Taysha Gene Therapies during the third quarter worth $85,000. Finally, Scientech Research LLC bought a new stake in shares of Taysha Gene Therapies during the second quarter worth $97,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.